Skip to main content

Table 2 Schedule of assessments

From: The efficacy of behavioural activation treatment for co-occurring depression and substance use disorder (the activate study): a randomized controlled trial

Domain

Measure

Screening

Baseline

Pre-allocation

3 month follow-up

12 month

Follow-up

Eligibility

Depression symptoms

Patient Health Questionnaire (PHQ-9) [56]

+

Depression screener

CIDI 3.0 Depression screener questions [54, 55]

+

Primary outcome measures

Substance dependence

CIDI 3.0 Substance dependence

(past month DSM-IV TR) [54]

Severity of Dependence Scale (SDS) [61]

+

+

+

+

+

+

Depression

CIDI 3.0 Major depression

(past month DSM-IV TR) [54, 55]

Beck Depression Inventory-II (BDI-II) [49]

+

+

+

+

+

+

Secondary outcome measures

Behavioural activation

Behavioural Activation for Depression Scale Short Form (BADS-SF; [70])

+

+

+

Anxiety

Beck Anxiety Inventory (BAI; [71])

+

+

+

Social phobia

CIDI 3.0 Social Phobia (past month DSM-IV-TR) [54]

Liebowitz Social Anxiety Scale [72, 73]

+

+

+

+

+

+

Traumatic events & trauma symptoms

PTSD trauma checklist from the CIDI 3.0 [54] and the Post-Traumatic Stress Disorder Checklist – Civilian Version (PCL-C; [74])

-

+

+

+

Borderline Personality Disorder

International Personality Disorders Examination (IPDE; [75])

+

+

+

Environmental Reward

Environmental Rewards Observation Scale (EROS; [76])

+

+

+

Rumination

Perseverative Thinking Questionnaire (PTQ; [77, 78]) and Ruminative Response Scale (RRS; [79])

+

+

+

Distress Tolerance

Distress Tolerance Scale (DTS; [80])

+

+

+

Sleep disturbance

Pittsburgh Sleep Quality Index (PSQI; [81])

+

+

+

Chronic physical conditions

As outlined by the Australian National Health Priority Area [82, 83]

+

+

+